Bora Pharmaceuticals (6472) Bora Pharmaceuticals Co., LTD. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Financial performance and growth

• Achieved revenue growth from $56 million in 2020 to $600 million in 2024, with a four-year CAGR of 117% and strong operating income and net profit growth.

• Market cap reached $2.4 billion, with 2,300+ employees and exports to over 100 countries.

• Return on equity averaged 30% and return on investment 15% over four years; annual shareholder return since 2018 is 93.9%.

• Market cap increased 7,000% since IPO, with efficient capital use and minimal dilution.

Business model and operational strategy

• Operates a dual-engine model: CDMO and commercial Rx businesses, creating synergies and operational efficiencies.

• CDMO business is high-growth, cash-generative, and resilient to economic cycles; commercial Rx focuses on high-barrier, high-margin brands.

• Ten manufacturing sites (five in North America, five in Taiwan) enable dynamic product allocation and scalability.

• End-to-end solutions with best-in-class quality metrics: 94% on-time in full, 95% right first time, and 100% batch success rate.

Recent achievements and investments

• Produced 2.8 billion doses in 2024, signed seven commercial MSAs, launched 16 new products, and delivered 40 new R&D molecules.

• Achieved a six-day turnaround and two-week onboarding; 140 new customer orders and preferred partner status for 30% of clients.

• 25 large molecule project wins in 2024; investing 20% of earnings into CapEx over five years, targeting 30%-40% IRR.

• Key acquisitions: Upsher-Smith (oral solid dose), Camden (injectables), and Tanvex (large molecule, FDA-approved facility).